CinDome, a CinRx portfolio company, is dedicated to filling the significant need for a safe, effective and tolerable treatment for the millions of people living with the devastating impact of chronic gastroparesis. With nearly 16 million adult patients in the US experiencing symptoms of gastroparesis, a safe and effective treatment tha
CinDome, a CinRx portfolio company, is dedicated to filling the significant need for a safe, effective and tolerable treatment for the millions of people living with the devastating impact of chronic gastroparesis. With nearly 16 million adult patients in the US experiencing symptoms of gastroparesis, a safe and effective treatment that can be taken on a chronic basis remains a significant unmet need. CinDome’s CIN-102 is an engineered formulation of domperidone, the first line treatment for gastroparesis worldwide, which is not approved in the US.
Deudomperidone (CIN-102) is a new chemical entity based upon deuteration and novel formulation of domperidone, a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States. In part due to safety concerns around QT prolongation, domperidone is not approved in the US. Deudomperidone has bee
Deudomperidone (CIN-102) is a new chemical entity based upon deuteration and novel formulation of domperidone, a frequently prescribed first line therapy for nausea, vomiting, and gastroparesis outside of the United States. In part due to safety concerns around QT prolongation, domperidone is not approved in the US. Deudomperidone has been engineered to alter the PK profile for sustained efficacy while significantly reducing cardiac liability. Currently, 20-50% of patients with gastroparesis use off-label treatments or go untreated, leaving a major unmet medical need and significant therapeutic development opportunity.
Multiple clinical trials of deudomperidone have been completed to date. Deudomperidone was well tolerated in these studies, and there were no sponsor-assessed drug related adverse events (AEs) or clinically meaningful laboratory abnormalities. Deudomperidone was deemed to have no meaningful impact on QT at exposures well above a therapeutic dose in a thorough QT study and demonstrated target engagement with trends of improvement in gastric emptying time in a previous Phase 2a trial.
Copyright © 2020 CinDome Pharma Inc. - All Rights Reserved.